Clinical trial
Phase I Using Velcade & Idarubicin in Elderly and Relapsed AML
NCT00382954 · University of Kentucky, Other · Completed
Key facts
| NCT number | NCT00382954 |
|---|---|
| Title | Phase I Using Velcade & Idarubicin in Elderly and Relapsed AML |
| Official title | A Phase I Study Using Bortezomib (Velcade, Formerly Known as PS-341) With Weekly Idarubicin for the Treatment of Elderly (>/= 60 Years) and Relapsed Patients With Acute Myelogenous Leukemia |
| Lead sponsor | University of Kentucky, Other |
| Collaborators | National Institutes of Health (NIH) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Acute Myelogenous Leukemia |
| Intervention type | Drug |
| Interventions | Velcade, Idarubicin |
| Enrollment | 55 |
| Start date | Feb 1, 2004 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Oct 2, 2006 |
| Last update posted | Sep 29, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: